Copenhagen, Denmark, 12th November 2018 - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has appointed Barbara Purcell to its Board of Directors with immediate effect.
Barbara is President of the Diversified Portfolio at multinational specialty pharmaceutical company Bausch Health and is a member of its Executive Management team. She has spent the past 25 years working in the pharmaceutical industry mostly managing mature brands and generics. Most recently she was instrumental in building the generic division at Bausch Health as well as revitalizing several mature brand assets there.
Previously, Barbara was Executive Director Global Sales and Marketing for Bausch + Lomb’s generics division, having also worked at Valeant, Novartis/Sandoz and Zydus.
She has an MBA from Rutgers University and a BA from the University of Pittsburgh and qualified as a Certified Public Accountant (CPA).
Commenting on the appointment, Steen Riisgaard, Chairman of the Board of Directors at Xellia Pharmaceuticals said: “We are pleased to welcome Barbara to the Board of Xellia. Barbara is an industry expert in successfully managing both generic and branded products in the US market. This combination of experiences should prove invaluable to Xellia as the Company continues to launch its injectable drug products in the US hospital market, whilst also remaining committed to its position as a leading trusted supplier of important anti-infective drugs. We look forward to working with Barbara as we provide support to Xellia’s management team in building a sustainable global business.
”
Barbara Purcell, said:
“This is an exciting time to join Xellia’s Board. With a newly established North American commercial organization, the launch of its first sterile injectable product under the Xellia brand and excellent R&D and manufacturing capabilities, the Company is in a strong position to continue to develop its portfolio of established and innovative products.”
Since 2014, Xellia has been developing a pipeline of value-added anti-infective drugs centred on formulation improvements for marketed drugs from its core portfolio. These products are intended to enhance patient care by providing convenience and ease of use for healthcare professionals. Earlier this year the Company submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its lead value-added product, Premixed Vancomycin Ready-to-Use (RTU) Bag. This product has also been granted Qualified Infectious Disease Product (QIDP) designation by the FDA.
For more information, please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Instinctif Partners (International media relations)
Eileen Paul / Rozi Morris / Melanie Toyne-Sewell
Tel: +44 (0) 20 7457 2020
Email: xellia@instinctif.com